

Factors Influence the Potential Drug Interaction Occurence among Hospitalized Patients with Cronic Kidney Disease at Labuang Baji Hospital Makassar

Raimundus Chaliks*

Pharmacy department of health polytechnic of the health ministry, Indonesia Email: roykhalik@yahoo.com

Abstract

Drug interactions (DIs) is one category of drugs related problems that may affect the clinical outcome of patients. Individuals with chronic kidney disease (CKD) often require multiple classes of drugs being at important risk for the development of DIs. The objective of this study was to determine the factors that influence to potential of drug interaction occurence in patients with CKD at Labuang BajiHospital Makassar. A cross-sectional study was conducted in April and May 2015. Number of sample was 82 medical records. The sample was selected by using a proportioned stratified sampling. The drug interaction was confirmed in the website http://www. drugs.com, Tatro Drug Interaction Fact, and Stockley's Drug Interactions. To determine the correlation between dependent and independent variables, Spearman's bivariate correlation (for, age, complication, number of drugs used, and lenght of stay) and Mann-Whitney's Comparative Test (for sex) were used. Results of analysis with Spearman Rho test found the three factors that influence to thepotential of drug interaction occurence were the number of drugs used (p = 0.000; r = 0.60) complications (p = 0.001; r = 0.356), and lenght of stay (p = 0.000; r = 0.405). This study conclusion that number of drugs used were risk factors strongly influence to the potential drug interaction occurence.

Keywords: drug interaction; chronic kidneydisease; Labuang Baji Hospital.

* Corresponding author.

1. Introduction

The increasing burden of patients with multiple disease conditions, drug therapy has grown more complex. In clinical practice, multiple drugs are often combined in the treatment of patients with chronic diseases. These associations generally produce drug interactions (DIs) with expected beneficial effects, but in some cases undesired outcomes may also occur, such as ineffective treatment and severe adverse events [1,2]. DIs are common in clinical practice. DI can be defined as the set of alterations introduced upon the therapeutic effect of a given drug stemming from the coadministration of one or more medications [2,3].

In the last decade, drug-drug interactions are progressive recognized as a very important part of the health services in most countries around the world [4]. This situation is caused by more evidence that indicate a great negative effects and serious clinical damage from various types of drug-drug interactions [5,6]. Drug-drug interactions appears as a cause of drug related problems (DRP) which, when present, produces negative impacts on morbidity, mortilitas, toxicity, liver and kidney damage, anemia, increased length of stay and cost of care, decreasing quality of life [7,8,9].

Drug interactions (DIs) are directly related to factors such as polypharmacy, aging, hepatic metabolism and decreased renal function. The incidence of kidney disease has increased significantly in recent years. Patients with renal impairment are at high risk against the potential of drug-drug interactions occurrence due to the large number and types of drugs they received and the effect of renal disease in drug excretion [10].

Several studies of drug-drug interactions in patients with chronic kidney disease have been conducted well in west and Asia Countries, including Indonesia. A study of drug interaction in patients with chronic kidney disease found 76.09% (474 cases) were detected drug interactions [11]. In the study was conducted in Centro clinical Hiperdia Minas at Brazil there were ten drugs most often prescribed for patients with CKD: furosemide (8.4%), simvastatin (7.1%), losartan (7.1%), acetylsalicylic acid (5, 2%), captopril (4.7%), hidroklortiazid (4.7%), omeprazole (4.5%), enalapril (4.1%), amlodipine (3.3%), and nifedipine (3, 1%) (8). While the result of study at Dr. Soedarso Hospital, Indonesiawas foundthe potential of drug interactions occur as much as 20% on prescriptions with <5 types of drugs and 46% on prescriptions with ≥ 5 types of drugs of 240 total sheets prescription [12].

Therefore, the potential of drug interactions that are commonly found in patients with chronic kidney disease prescriptions can cause serious adverse event if it is not detected as early as possible. Finally Drug interactions need to be considered because it can affect the body's response to treatment [13]. The data obtained from this study will be very helpful for the nephrologists in the therapeutic management of patients with CKD effectively. Furthermore, the results of this study are very helpful physicians, clinical pharmacists, and nurses to intervene, prevent and reduce morbidity due to adverse effects of drug interactions.

2. Materials and Methods

This cross-sectional retrospective observational study was carried out at the Labuang BajiHospital Makassarcovering the period April and May 2015. The population of this study was allofmedical records of

inpatiens with CKD. The samples used weremedical recordsof inpatients. The samples wereselected by using *Proportioned Stratified Sampling* technique. The samplewere determine by using Slovin formula with an error rate of 5%. The number of samples given by the formula were 2 medical records.

2.1 Inclusion criteria

- 1) Medical records of inpatient in Labuang BajiHospital Makassar for the period of January-December 2014.
- 2) The patients of between 15 and 80 years of age.
- 3) The patients who were given two or more drugs.

2.2 Eexclusions criteria

- 1) The patients who were given one drug so that drug-drug interaction could not be identified.
- 2) Patients with the stroked is ease.
- 3) Incomplete records.

2.3 Data collection

The data were collected by gathering medical records of pediatric inpatient at Labuang Baji hospital, Makassar for the period of January-December 2014. The kinds of data collected were demography, number of drugs used, complication, length of stay, and and duration of disease. The drugs written in the medical records were checked for the potential drug interaction in website http://www.drugs.com and Tatro Drug Interaction Facts (2014) andStockley's Drug Interaction (2014).

2.4 Data analysis

Descriptive analysis was performed using frequencies for categorical variables. Sperman bivariate correlation analysis using to determine independent variablesofage, complications, number of drugs used, length of stay, and the dependent variable, that is, the number of potential drug interaction occurrences. In addition, Mann-Whitney of comparative test was used to find out the correlation between sex and potential drug interaction occurrences.

3. Results

3.1 Characteristics of subjects

Based on study has been conducted, 82 medical records of inpatients with CKD were included. Characteristics of subjects was shown in Table 1.

3.2 The factors related to potential drug interaction occurrences

Based on statistical analyses, the factors-related to potential drug interaction occurrences wasshown in Table2.

Variables					
	Y	Yes		No	Total
	n	%	n	%	
Sex					
Male	16	37.2	19	48.7	35
Female	27	62.8	20	51.3	47
Age (Year)					
< 35	5	11.6	5	12.8	10
35-55	20	46.5	22	56.4	42
> 55	18	41.9	12	30.8	30
Complication					
uncomplication	3	7.0	9	23.1	12
1	12	27.9	18	46.2	30
≥ 2	28	65.1	12	30.8	40
number of drugs used					
3	2	4.7	16	41.0	18
4-6	7	16.3	15	38.5	22
> 6	34	79.1	8	20.5	42
Length of stay (days)					
< 3	3	7.0	16	41.0	19
4-6	19	44.2	15	38.5	34
> 6	21	48.8	8	20.5	29

Table1: Distribution of potential drug interactions occurrence of characteristics of subjectsat Labuang BajiMakassar Hospital for period January-December 2014 (n = 82)

Interaction				Analysis	Correlation
Yes		No			
n	%	n	%	-	(r)
				Mann	
				<i>Whitney</i> Cmparative	
15	36.6	20	48,8	test	
26	63.4	21	51.2	(p = 0.296)	
				Spearman bivariate	
				correlation	
4	9.8	6	14.6		
				(p = 0.369)	0.101
19	46.3	23	56.1		
18	43.9	12	29.3		
				Spearman bivariate	
				correlation	
3	7.3	9	22.0		
				(p = 0.001)	0.356
12	29.3	18	43.9		
26	63.4	14	34.1		
				Spearman bivariate	
				correlation	
1	2.4	8	19,5		
_				(p = 0.000)	0.600
8	19.5	16	39.0		
32	78.0	17	41.5		
				Spearman bivariate	
				correlation	
3	7.3	16	39.0		
				(p = 0.000)	0.405
16	39.0	17	41.5		
22	537	8	19.5		
	n 15 26 4 19 18 3 12 26 1 8 32 3 16 22	Yes n % 15 36.6 26 63.4 4 9.8 19 46.3 18 43.9 3 7.3 12 29.3 26 63.4 1 2.4 8 19.5 32 78.0 3 7.3 16 39.0	Interaction Yes 1 n % n 15 36.6 20 26 63.4 21 4 9.8 6 19 46.3 23 18 43.9 12 3 7.3 9 12 29.3 18 26 63.4 14 1 2.4 8 8 19.5 16 32 78.0 17 3 7.3 16 16 39.0 17	Interaction Yes No n % n % 15 36.6 20 48,8 26 63.4 21 51.2 4 9.8 6 14.6 19 46.3 23 56.1 18 43.9 12 29.3 3 7.3 9 22.0 12 29.3 18 43.9 26 63.4 14 34.1 1 2.4 8 19,5 8 19.5 16 39.0 32 78.0 17 41.5 3 7.3 16 39.0 16 39.0 17 41.5	Interaction Analysis Yes No Analysis n % n % 15 36.6 20 48,8 WhitneyCmparative test 26 63.4 21 51.2 (p = 0.296) Spearman bivariate correlation 4 9.8 6 14.6 (p = 0.369) 19 46.3 23 56.1 (p = 0.369) 18 43.9 12 29.3 Spearman bivariate correlation 3 7.3 9 22.0 (p = 0.001) 12 29.3 18 43.9 (p = 0.001) 12 29.3 18 43.9 (p = 0.001) 12 29.3 18 43.9 (p = 0.000) 8 19.5 16 39.0 (p = 0.000) 3 7.3 16 39.0 (p = 0.000) 3 7.3 16 39.0 (p = 0.000) 3 7.3 16 39.0 (p = 0.000)

Table 2: The Factors related to potential of drug interactions occurrence of inpatient with CKD at Labuang BajiHospital Makassar for period January-December 2014(n =82)

4. Discussion

The factors related to the potential drug interaction occurrences, according to Spearman, the potential of drug interaction occurrence were the number of drugs used (p=0,000), lenght of stay (p=0.000), and complication (p=0.000). The number of drugs used has a strong correlation and influence with potential drug interactions (r=0.600), while lenght of stay and complication has weak correlation (r=0.405) and (p=0.365). This conclusion is confirmed by the standard proposed by [14], which states that r= 0.50-1.00 shows a strong correlation and r<0.50 shows weak correlation. On the other hand, the age factor did not show any significant correlation with potential drug interactions (p=0.369), which means that the correlation is not significant since p >0,05.

This studyaccording to by [11. 15. 16] which state that the number of drugs used have correlation with the potential drug interaction (p = 0.000), (p=0.006), and (p=0.026). Another research by [17] also support this study that state the patients with greater number of prescribed medications is very high potential for drug interactions with AOR = 4.09 and p = 0.000. The study was conducted by [18] also shown the number of drugs sed significantly influence topotential drug interaction which the risk of drug interactions increase of 3-5 drugs given with OR = 4.74 and for the number of drug given ≥ 6 has OR = 23.03 and p = 0.001. While the study was conducted by [19]) wasshown there is a significant correlation between the number one prescription drug with potential of drug interactions occurrence with p < 0.05 and the drug interactions occurrence was increased 6 times higher in recipes containing ≥ 5 type of drugs than < 5. The Mann-Whitney comparative test results showed that sex and potential drug interaction occurrences did not show any significant difference (p>0.05), which means that sex factor has no connection with drug interaction occurrences.

5. Conclusion

Based on the statistical analysis on factors influencing drug interactions at Labuang Baji Hospital, Makassar, it can be concluded that: the number of drugs used has a strong influence and correlation with the potential drug interactions occurrencewhile length of stay and complication has weak correlation. However, age and sex do not have any correlation with the potential drug interaction occurrences

Funding: No funding sources

Conflict of interest: None declared

Aknowledgment

This study project would not have been possible without the support of many people. I thank to the Labuang Baji Hospital for allowing me to conduct the study, Ashari Rasjid, Director of health polytechnic of the health ministry, Rusli, Chair of pharmacy department for support to thestudy and Anwar Mallogi who more assist for reviewing the manuscript andpublication. I wishes to express my love and gratitude to my family for their understanding through the duration of the study.Without which the present study could not have been completed.

References

[1] Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf 2010;33:667-75. DOI: http://dx.doi. org/10.2165/11534400-000000000-00000.

[2] Pirmohamed M. Drug-drug interactions and adverse drug reactions: separating the wheat from the chaff. Wien KlinWochenschr 2010;122:62-4. PMID: 20213370 DOI: http://dx.doi.org/10.1007/s00508-010-1309-1.

[3] Robertson S, Penzak S. Drug interactions. In: Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP. Principles of clinical pharmacology. 2nd ed. Burlington: Elsevier Academic Press; 2007. p.229-47.

[4] Rijkom Z et al. Frequency and nature of drug–drug interactions in a Dutch university hospital. British Journal of Clinical Pharmacology 2009; 68:2:187-193. DOI:10.1111/j.1365-2125.2009.03443.x.

[5] Bagheri H,Michel F, Lapeyre-Mestre M, Lagier E, Cambus JP, Valdiguie P, Montastruc JL. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J ClinPharmacol 2000; 50:479–84.

[6] Juurlink DN,Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug–drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289:1652–8.

[7] Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ. Medication-related problems inCKD. Adv Chronic Kidney Dis 2010;17:404-12.DOI: http://dx.doi.org/10.1053/j.ackd.2010.06.004.

[8] Mason NA. Polypharmacy and medication-related complications in the chronic kidney disease patient. CurrOpinNephrolHypertens 2011;20:492-7. DOI: http://dx.doi.org/10.1097/ MNH.0b013e328349c261.

[9] Baxter K. Stockley's Drug Interactions: a Source Book of Interactions, their Mechanisms, Clinical Importance and Management. 10th Edition. London: Great Britain Pharmaceutical Press; 2014.

[10] Marquito AB.Identifying potential drug interactions in chronic kidney disease patients, *J Bras Nefrol* 2014;36(1):26-34. DOI: 10.5935/0101-2800.20140006.

[11] Rama M.Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian J Pharm Sci 2012;74:63-8. DOI: http://dx.doi.org/10.4103/0250-474X.102545

[12] MayasariE.AnalisisPotensiInteraksiAntidiabetikInjeksi Insulin padaPeresepanPasienRawatJalanPeserta
Askes RS DokterSoedarso Pontianak Periode April-Juni 2013, Skripsi
2015.Tidakditerbitkan.UniversitasTanjungpura, Pontianak.

[13] Irnawati, Hajar. AnalisisFaktor Yang Berpengaruh Terhadap KejadianInteraksi Obat Pada Pasien Geriatr iPenyakit KardiovaskulerRawatInap Di RsudLabuangBaji Makassar. Karya TulisIlmiah. 2014. Tidakditerbitkan. PoliteknikKesehatan Makassar.

[14] Cohen J. Statistical Power Analysis for the Behavioral Sciences. Dalam SPSS Survival Manual. 2nd Edition, Chapter 11. Sidney: Allen and Unwin; 1988: p. 126.

[15] Manik UC et al. A retrospective study on drug interaction for pediatric in-patients at Central Public Hospital Haji Adam Malik, Medan for the period of January-June 2012. International Journal of Basic & Clinical Pharmacology 2014;3:3:512-516. Doi: 10.5455/2319-2003.ijbcp20140619. p. 512-516.

[16] SetiawanT, StudiRetrospektifInteraksiObatpadaPasienJamkesmas di RSUD HasanuddinDamrah Manna Bengkulu Selatan, Skripsi2011.Tidakditerbitkan.Universitas Sumatra Utara, Medan.

[17] Chelkeba L. Alemseged F,Bedada W. Assessment of potential drug-drug intractions among out patients receiving cardiovascular medications at Jimma University specialized hospital. South West Ethiophia. International Journal of Basic & Clinical Pharmacology 2013;2:144-152

[18] Teixeira JJV.et al. Potential Drug-Drug Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern Brazil., www.plosone.org vol.7, issue 10.

[19] Utami M. AnalisisPotensiInteraksiObatAntidiabetik Oral PadaPasien Di InstalasiRawatJalanAskes RS DokterSoedarso Pontianak.Skripsi 2013.Tidakditerbitkan. UniversitasTanjungpuraPontianak.